Prospects for Pharmacologic Inhibition of Hepatic Glucose Production

Author(s): R. Kurukulasuriya, J. T. Link, D. J. Madar, Z. Pei, J. J. Rohde, S. J. Richards, A. J. Souers, B. G. Szczepankiewicz

Journal Name: Current Medicinal Chemistry

Volume 10 , Issue 2 , 2003

Become EABM
Become Reviewer
Call for Editor


Type 2 diabetes is a widespread disease where effective pharmacologic therapies can have a profound beneficial public health impact. Increased hepatic glucose production (HGP) is observed in diabetics and its moderation by currently available agents provides therapeutic benefits. This review describes the challenges associated with the discovery of small molecules that inhibit HGP. Gluconeogenesis, glycogenolysis, liver architecture, and hepatocyte composition are described to provide background information on hepatic function. Current methods of target validation for drug discovery, HGP measurement, diabetes animal models, as well as current drug therapies are covered. In the accompanying review article the new drug targets being probed to produce the next generation of therapies are described. Significant pharmaceutical and academic efforts to pharmacologically inhibit HGP has the opportunity to provide new therapeutics for type 2 diabetics.

Keywords: hepatic glucose production, diabetes, hyperglycemia, metformin, gluconeogenesis, glycogenolysis, liver, liver targeting

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [99 - 121]
Pages: 23
DOI: 10.2174/0929867033368547
Price: $65

Article Metrics

PDF: 1